Back
The Scenario
An investment company had a novel clinical trial software product in its sights, and the upside looked real, but so did the risk: the category was young, the competition unmapped, and the regulatory ground shifting under the new ICH E6 (R2) guidelines.
The investor needed a partner who could knowledgeably assess a new clinical trial software on both technical merit and market potential, and one who could move fast...
